August 6, 2015

Aurobindo Pharma Limited on Tuesday received approval from the Food and Drug Administration for its alprazolam tablets, a generic version of Xanax. 

July 13, 2015

Otsuka Pharmaceutical and H. Lundbeck A/S announced Friday that their new medication Rexulti (brexpiprazole) had been approved by the Food and Drug Administration as an adjunctive treatment for major depressive disorder (MDD) and a treament for schizophrenia. 

June 15, 2015

In the past 12 months ended April 19, Zyrtec (McNeil Consumer Healthcare) continues to dominate the allergy category with total retail sales of $332 million.

June 11, 2015

Loblaw has announced that by the end of 2018, its private brands Life Brand and President's Choice household, beauty and cosmetic products will no longer be formulated using triclosan, phthalates or micro beads.

June 4, 2015

Sandoz has announced that it is introducing guanfacine hydrochloride extended-release tablets, a generic version of Intuniv, in 1-, 2-, 3- and 4-mg dosages.

June 2, 2015

The latest addition to Teva’s roster of medication is its generic version of Intuniv (guanfacine) extended release tablets, a non-stimulant meant to treat attention deficit hyperactivity disorder.

May 27, 2015

Consumers in the Western United States don't plan on purchasing as many allergy medicines, a Field Agent survey found. 

April 29, 2015

Teva Pharmaceutical announced the launch of aripiprazole tablets in 2-, 5-, 10-, 15, 20- and 30-mg strengths in the United States.

March 31, 2015

Teva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension. 

 

March 13, 2015

Actavis on Friday announced that the Food and Drug Administration approved Saphris for the treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients.

March 10, 2015

Actavis expanded its portfolio of topicals with the launch of a generic corticosteroid.

February 10, 2015

A new study funded by the Bay Area Lyme Foundation and conducted by Stanford School of Medicine researchers has found that loratadine may be able to help treat Lyme disease.

January 27, 2015

Symplmed Pharmaceuticals announced that the Food and Drug Administration approved Prestalia (perindopril arginine and amlodipine) tablets to treat hypertension. 

January 21, 2015

Eisai on Tuesday announced the launch of a new savings card for Belviq (lorcaserin HCl) CIV, the most-prescribed branded FDA-approved prescription drug therapy for chronic weight management.

January 12, 2015

Perrigo on Monday announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex spray, 0.05%. 

January 9, 2015

Daiichi Sankyo Co., Limited on Friday announced that the Food and Drug Administration has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor that reduces the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. 

 

December 29, 2014

Genentech last week announced that the Food and Drug Administration approved a supplemental biologics license application for Gazyva to be used in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia.

December 19, 2014

Teva Pharmaceutical announced that the Food and Drug Administration approved QNasl (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis in children ages 4 years to 11 years.

December 4, 2014

Camber Pharmaceuticals announced the addition of montelukast sodium tablets to its portfolio of products.

December 2, 2014

Perrigo on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for diclofenac sodium topical solution 1.5% w/w.

November 7, 2014

Teva Pharmaceutical on Friday announced positive findings from a Phase III clinical study that examined the safety and efficacy of Qnasl.

October 22, 2014

A JAMA study noted that about two-thirds of dietary supplements recalled by the Food and Drug Administration still contained banned ingredients at least six months after being recalled.

September 30, 2014

Par Pharmaceutical on Tuesday announced that it has started shipping amlodipine and valsartan tablets in all four dosage strengths.

August 25, 2014

Pharmaceutical company Iroko announced today that a new version its anti-inflammatory drug Zorvolex had been approved by the Food and Drug Administration.